Deterministic cost-effectiveness analysis results of the scenario analysis.

<p>Deterministic cost-effectiveness analysis results of the scenario analysis.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Bart Slob (20410220) (author)
مؤلفون آخرون:	Tanja Fens (10527375) (author), Maaike Weersma (20410223) (author), Maarten Postma (353794) (author), Cornelis Boersma (845072) (author), Lisa de Jong (20410226) (author)
منشور في:	2024
الموضوعات:	Medicine Sociology Marine Biology Cancer Infectious Diseases Virology Biological Sciences not elsewhere classified indicating total savings however yet unknown general population mortality dutch pharmacoeconomic guidelines adjusted life years 06 life years preventing disease progression chronic kidney disease dominant alternative compared sensitivity analyses confirmed probabilistic sensitivity analyses simulating kidney progression min per 1 cost saving compared qalys ), compared netherlands </ p empagliflozin plus soc kidney trial utilities ), 79 qalys 22 qalys ckd progression xlink "> uncertainty around societal perspective soc alone published data pay threshold national sources lifetime horizon kdigo classification input data incremental cost event costs effectiveness ratio effectiveness analysis done according diabetes status current soc cost effectiveness cost effective conducted using baseline characteristics adult patients additional 1 90 ml 574 respectively 01 quality &# 8364
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة